NCPA outraged at low reimbursement for generic Zocor
Complaints from NCPA members have been steadily building over low maximum allowable cost (MAC) reimbursement from Express Scripts for generic Zocor. According to NCPA, it has received numerous reports that Express Scripts, one of the largest PBMs in the country, has set a MAC for simvastatin at approximately two-thirds of the pharmacy acquisition price.
NCPA outraged at low reimbursement for generic Zocor
Complaints from NCPA members have been steadily building over low maximum allowable cost (MAC) reimbursement from Express Scripts for generic Zocor. According to NCPA, it has received numerous reports that Express Scripts, one of the largest PBMs in the country, has set a MAC for simvastatin at approximately two-thirds of the pharmacy acquisition price. The association has also reported that other PBMs may be following suit. NCPA has met with members of Congress in an effort to correct what it called "an abusive practice." On a related note, the association reported that some PBMs have moved Zocor into a tier-one or generic co-pay category, reimbursing pharmacies at the generic rate even though the plan is requiring that Zocor, a brand drug, be dispensed.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
